GlassScriptPhysician profile
Charles Ray Longanecker
NPI 1346476785
$10,206.50
in general payments reported to CMS, 2019-2025
38 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,504 · 2022: $2,365 · 2023: $1,911 · 2024: $1,930 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,337.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,117.96 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $946.18 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $739.16 | 2021-2025 | |
| Lilly USA, LLC | $674.19 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $663.13 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $581.73 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $473.12 | 2021-2022 | |
| Pfizer INC. | $411.72 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $405.34 | 2021-2024 | Nuzyra |
| Axsome Therapeutics, INC. | $374.51 | 2024-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $229.73 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Exact Sciences Corporation | $206.22 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $205.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $184.63 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Longanecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.